Literature DB >> 21867914

XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids.

Sascha Feuerhahn1, Christophe Giraudon, Marta Martínez-Díez, Juan A Bueren-Calabuig, Carlos M Galmarini, Federico Gago, Jean-Marc Egly.   

Abstract

Trabectedin and Zalypsis are two potent anticancer tetrahydroisoquinoline alkaloids that can form a covalent bond with the amino group of a guanine in selected triplets of DNA duplexes and eventually give rise to double-strand breaks. Using well-defined in vitro and in vivo assays, we show that the resulting DNA adducts stimulate, in a concentration-dependent manner, cleavage by the XPF/ERCC1 nuclease on the strand opposite to that bonded by the drug. They also inhibit RNA synthesis by: (1) preventing binding of transcription factors like Sp1 to DNA, and (2) arresting elongating RNA polymerase II at the same nucleotide position regardless of the strand they are located on. Structural models provide a rationale for these findings and highlight the similarity between this type of DNA modification and an interstrand crosslink.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21867914     DOI: 10.1016/j.chembiol.2011.06.007

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  18 in total

Review 1.  Ecteinascidins. A review of the chemistry, biology and clinical utility of potent tetrahydroisoquinoline antitumor antibiotics.

Authors:  V H Le; M Inai; R M Williams; T Kan
Journal:  Nat Prod Rep       Date:  2015-02       Impact factor: 13.423

Review 2.  Enriching cancer pharmacology with drugs of marine origin.

Authors:  Paula C Jimenez; Diego V Wilke; Paola C Branco; Anelize Bauermeister; Paula Rezende-Teixeira; Susana P Gaudêncio; Leticia V Costa-Lotufo
Journal:  Br J Pharmacol       Date:  2019-12-23       Impact factor: 8.739

3.  Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway.

Authors:  Sandra Martínez; Laura Pérez; Carlos M Galmarini; Miguel Aracil; Juan C Tercero; Federico Gago; Beatriz Albella; Juan A Bueren
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

4.  Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations.

Authors:  Juan A Bueren-Calabuig; Christophe Giraudon; Carlos M Galmarini; Jean Marc Egly; Federico Gago
Journal:  Nucleic Acids Res       Date:  2011-07-03       Impact factor: 16.971

Review 5.  Trabectedin for advanced soft tissue sarcomas: optimizing use.

Authors:  Alison Reid; Juan Martin-Liberal; Charlotte Benson
Journal:  Ther Clin Risk Manag       Date:  2014-12-12       Impact factor: 2.423

Review 6.  Trabectedin, a drug acting on both cancer cells and the tumour microenvironment.

Authors:  M D'Incalci; N Badri; C M Galmarini; P Allavena
Journal:  Br J Cancer       Date:  2014-04-22       Impact factor: 7.640

Review 7.  Trabectedin therapy as an emerging treatment strategy for recurrent platinum-sensitive ovarian cancer.

Authors:  José Antonio López-Guerrero; Ignacio Romero; Andrés Poveda
Journal:  Chin J Cancer       Date:  2015-01

8.  Insight into the sequence-specific elements leading to increased DNA bending and ligase-mediated circularization propensity by antitumor trabectedin.

Authors:  Alberto Mills; Federico Gago
Journal:  J Comput Aided Mol Des       Date:  2021-06-09       Impact factor: 3.686

Review 9.  Trabectedin and plitidepsin: drugs from the sea that strike the tumor microenvironment.

Authors:  Carlos M Galmarini; Maurizio D'Incalci; Paola Allavena
Journal:  Mar Drugs       Date:  2014-01-27       Impact factor: 5.118

10.  Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.

Authors:  Michelle Lima; Hana Bouzid; Daniele G Soares; Frédéric Selle; Claire Morel; Carlos M Galmarini; João A P Henriques; Annette K Larsen; Alexandre E Escargueil
Journal:  Oncotarget       Date:  2016-05-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.